- Home
- NRXS vs QTTB Comparison
NRXS vs QTTB Comparison
Compare NRXS & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- QTTB
- Stock Information
- Founded
- NRXS 2011
- QTTB 2015
- Country
- NRXS United States
- QTTB United States
- Employees
- NRXS N/A
- QTTB N/A
- Industry
- NRXS
- QTTB Biotechnology: Pharmaceutical Preparations
- Sector
- NRXS
- QTTB Health Care
- Exchange
- NRXS Nasdaq
- QTTB Nasdaq
- Market Cap
- NRXS 25.0M
- QTTB 23.3M
- IPO Year
- NRXS 2023
- QTTB N/A
- Fundamental
- Price
- NRXS $2.57
- QTTB $1.77
- Analyst Decision
- NRXS Strong Buy
- QTTB Hold
- Analyst Count
- NRXS 1
- QTTB 8
- Target Price
- NRXS $7.00
- QTTB $24.00
- AVG Volume (30 Days)
- NRXS 36.2K
- QTTB 70.2K
- Earning Date
- NRXS 11-11-2025
- QTTB 11-06-2025
- Dividend Yield
- NRXS N/A
- QTTB N/A
- EPS Growth
- NRXS N/A
- QTTB N/A
- EPS
- NRXS N/A
- QTTB N/A
- Revenue
- NRXS $3,217,531.00
- QTTB N/A
- Revenue This Year
- NRXS $62.14
- QTTB N/A
- Revenue Next Year
- NRXS $131.87
- QTTB N/A
- P/E Ratio
- NRXS N/A
- QTTB N/A
- Revenue Growth
- NRXS 41.93
- QTTB N/A
- 52 Week Low
- NRXS $1.33
- QTTB $1.35
- 52 Week High
- NRXS $6.20
- QTTB $53.17
- Technical
- Relative Strength Index (RSI)
- NRXS 55.99
- QTTB 49.44
- Support Level
- NRXS $2.31
- QTTB $1.76
- Resistance Level
- NRXS $2.65
- QTTB $1.90
- Average True Range (ATR)
- NRXS 0.10
- QTTB 0.14
- MACD
- NRXS 0.01
- QTTB 0.01
- Stochastic Oscillator
- NRXS 67.57
- QTTB 52.63
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.